Dimethylsulfoxide (DMSO) was shown to inhibit the proliferation of several B cell lines including Raji, Daudi, and SKW6-CL4 but the mechanisms involved in this growth arrest are still unclear. We show that in 7TD1 mouse hybridoma cells a DMSO-induced reversible G 1 arrest involves inactivation of Rb kinases, cyclin D2/ CDK4 and cyclin E/CDK2. This occurs by at least three distinct mechanisms. Inhibition of cyclin D2 neosynthesis leads to a dramatic decrease of cyclinD2/CDK4 complexes. This in turn enables the redistribution of p27 [KIP1] from cyclin D2/CDK4 to cyclin E/CDK2 complexes. In addition, the simultaneous accumulation of p21
Introduction
Cell cycle progression is punctuated by several transition points (Pardee, 1989) and the passage through these checkpoints is controlled by the activation of dierent cyclins/CDKs complexes (Morgan, 1995; Reed, 1992; Sherr, 1994 Sherr, , 1995 . Progression through G 1 phase and transition from G 1 into S phase are regulated by cyclin D, E and A-associated kinases. D-type cyclins (D1, D2 and D3) in association with CDK4 and CDK6 (for review see: Sherr, 1994 ) phosphorylate the retinoblastoma protein (pRb) in mid G 1 , which is an essential step in G 1 /S transition (Dowdy et al., 1993; Kato et al., 1993; Matsushime et al., 1994; Resnitzky and Reed, 1995) .
Cyclin E/CDK2 is transiently activated during late G 1 and early S phase and probably regulates G 1 to S transition (Dulic et al., 1992; Knoblich et al., 1994; Ko et al., 1992; Resnitszky et al., 1994) . In addition to G 1 cyclins, cyclin A/CDK2 is also required for S phase entry (Girard et al., 1992; Pagano et al., 1992) . Two families of CDK inhibitors regulating CDK activities and cell progression have been identi®ed. Members of KIP family, include p21 [CIP1] , p27 [KIP1] and p57 [KIP2] , that bind to and inhibit most of cyclin/CDKs complexes. INK family is composed of the p15 [INK4B] , p16 [INK4A] , p18 [INK4C] and p19 [INK4D] members. These INK inhibitors induce G 1 arrest by associating exclusively with CDK4 and CDK6 thus preventing their association with cyclin D (for review see: Sherr and Roberts, 1995) .
Growth inhibition and cell cycle arrest in G 1 may be induced by a wide variety of factors such as TGFb (Florenes et al., 1996; Reynisdottir et al., 1995) , nerve growth factor (Decker, 1995) , alpha interferon (Tiefenbrun et al., 1996) , ®brillar collagen (Koyoma et al., 1996) , prostaglandin A2 (Gorospe et al., 1996) , antiprogestin (Musgrove et al., 1997) or by antiproliferative agents such as cyclic-AMP , staurosporine (Schnier et al., 1996) , lovastatin (Hengst et al., 1994) . To date, the mechanisms underlying these antiproliferative eects are a matter of great interest. Several lines of evidence have demonstrated that these molecules inhibit cell progression through dierent mechanisms such as alteration of the CDK expression, modi®cation of cyclin levels (Gorospe et al., 1996; L'Allemain et al., 1997; Poon et al., 1995; Tiefenbrun et al., 1996) , regulation of CDK activity through phosphorylation/dephosphorylation (Tiefenbrun et al., 1996) and induction or redistribution of CDK inhibitors (CKIs) (Florenes et al., 1996; Hengst et al., 1994; Koyoma et al., 1996; Poon et al., 1995; Reynisdottir et al., 1995) .
Dimethylsulfoxide (DMSO) has been reported to induce both growth arrest and dierentiation of myeloid (Hiroguchi-Yamada and Yamada, 1993; Klinken et al., 1988) or neuroblastoma cell lines (Kimhi et al., 1976; Kranenburg et al., 1995) but in these cell systems it is dicult to discriminate the molecular events involved in growth arrest to those that are necessary for cellular dierentiation. We show that, in the hybridoma 7TD1 cells, like in other B cell lines such as Raji, Molt 4 or SKW6-CL4 (Sawai et al., 1990; Takase et al., 1992 Takase et al., , 1994 Teroaka et al., 1996) exposure to DMSO arrests the cells in G 1 phase, without inducing dierentiation or apoptosis. We observe that this growth inhibition is the result of the combined action of cyclin D2 inhibition and association of p27 [KIP1] and p21 [CIP1] with cyclin/CDK4 and cyclin/CDK2 complexes.
7TD1 cells with 1.5% DMSO for 15 h, led to a complete block of cell proliferation. As shown by FACS analysis, more than 92% of the cells were blocked in G 1 phase (Figure 1a ). This arrest was not toxic and was reversible as following drug withdrawal 7TD1 cells entered synchronously in S phase (more than 90%) after 12 h and divided 24 h after growth reinitiation (Figure 1b) .
DMSO abrogated cyclin D2/CDK4 activity and impaired pRb phosphorylation
To get insight into the molecular basis confering DMSOinduced G 1 arrest, we have studied several events known to regulate G 1 phase progression, such as pRb phosphorylation and cyclin/CDK activities.
High density 7TD1 cell culture (8610 5 cells/ml) was diluted into fresh medium (3.5610 5 cells) containing or not 1.5% DMSO and pRb phosphorylation, CDK4 activity and cyclin D expression (Figures 2b, 3a and b) were analysed after respectively 2, 4, 6, 8 and 12 h. At high density (8610 5 cells/ml) the 7TD1 cells continued to divide albeit with a slight increasing cell death rate (data not shown) suggesting that many aspects of the cell cycle are not perturbed by high density. Two hours after cell dilution the mitotic cell population present in the culture was unchanged (cf FACS analysis in Figure 2a ). However the presence of hypophosphorylated pRb (Figure 2b) , the low levels of cyclin D2 and the weak CDK4 activity (Figure 3 ) suggested that in these cells there exists a sort of uncoupling between growth factor sensing regulators , cyclin D3 and D2 expression. CDK4 level was analysed by Western blotting, whereas cyclin D3 and D2 were measured both at mRNA and protein levels. Northern blot were carried out using 20 mg of total RNA that were revealed using human cyl 3 and cyl 2 full lengh cDNAs. Western blotting were carried out from 100 mg of protein extracts and proteins were revealed with anticyclin D3 or anti-cyclin D2 antibodies as described in Materials and methods. (c) Lysates from cells incubated with (+) or without (7) 1.5% of DMSO for 4, 6 and 8 h were immunoprecipitated (IP) with anti-CDK4 antibodies and the level of cyclin D2 in immunoprecipitates was analysed by Western blot (WB). (d) Relative contribution of cyclin D2 and cyclin D3 in CDK4 activity. Lysates from cells treated with (+) or without (7) DMSO for 8 h were immunoprecipitated with anti-CDK4 (a-CDK4), anti-cyclin D2 (a-D2) or anti-cyclin D3 (a-D3) antibodies and immunoprecipitates were assayed for their kinase activity using GST-pRb as substrate i.e. cyclin D (Sherr, 1994) and the cyclins responsible for DNA replication and mitosis (cyclins E, A and B). Thus, in contrast to other cell types like ®broblats, where pRb phosphorylation occurs throughout the cell cycle (Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989 DeCaprio et al., , 1992 Mihara et al., 1989) it appears that in 7TD1 cells pRb is phosphorylated predominantly by cyclin D2/CDK4. Indeed, 4 h after the addition of fresh medium, pRb became phosphorylated ( Figure 2b ) concomitantly with the increase of cyclin D2 levels (Figure 3b ) and the augmentation of cyclin D2/CDK4-associated kinase activity (Figure 3a) . In the presence of 1.5% DMSO, pRb remained underphosphorylated (Figure 2b ) and CDK4 kinase activity decreased gradually to reach a maximal inhibition (90%) 8 h after drug addition (Figure 3a and inset) .
To further investigate the mechanisms underlying CDK4 inhibition we tested the eect of DMSO on the expression of CDK4 and D-type cyclins. Cyclin D1 being absent in 7TD1 cells, we focused our attention on the regulation by DMSO of cyclin D2 and D3. Western blot analysis showed that DMSO treatment did not modify the steady state levels expression of CDK4 ( Figure 3b ). By contrast, DMSO blocked the increase of cyclin D2 mediated by the addition of fresh medium and consequently decreased the level of cyclin D2/CDK4 complexes ( Figure 3b and c respectively) with a kinetic pro®le that matched with CDK4 activity. In contrast to cyclin D2, addition of fresh medium resulted in a slight diminution of cyclin D3 mRNA which seemed to be prevented by DMSO. However, the protein level of cyclin D3 appeared not to be aected by these treatments.
Since CDK4 can associate with both cyclin D2 or D3, we addressed the question which cyclin preferentially activated CDK4 in 7TD1 cells. Cyclin D2 and D3 were immunoprecipitated from lysates of cells treated or not with DMSO and were assayed for their capacity to phosphorylate recombinant pRb by in vitro kinase assay. As shown in Figure 3d , essentially all pRb kinase activity was due to cyclin D2/CDK4 complexes. This result was con®rmed by Western blot experiments indicating that cyclin D3/CDK4 represented 5 ± 10 % of total cyclin D/CDK4 complexes (data not shown).
Taken at their face value, these data suggested that, in 7TD1 cells, cyclin D2 was mainly involved in the control of CDK4 kinase activity. However we cannot exclude a minor participation of cyclin D3-activated CDK4.
DMSO inhibits sequentially cyclin E and cyclin A/CDK2 activities
As CDK2 activity is required for S phase entry, we sought to determine the eect of DMSO on this kinase by analysing the activities of cyclin E/CDK2 and cyclin A/CDK2 complexes. To this end we immunoprecipitated CDK2, cyclin A and cyclin E complexes from lysates of cells incubated, for indicated times, with or without DMSO and tested the associated kinase activity using histone H1 as a substrate. Total CDK2 activity did not vary signi®cantly following cell dilution in fresh medium but was inhibited in presence of DMSO (t 1/2 inhibition = 8 ± 9 h) (Figure 4a ). Moreover, we found that under these experimental conditions, inactivation of cyclin E/CDK2 kinase (t 1/2 inhibition = 4 ± 5 h) preceded that of cyclin A/CDK2 (t 1/2 inhibition = 9 ± 10 h) ( Figure 4a ). Western blot analysis has shown that inactivation of cyclin E/CDK2 can not be attributed to DMSO-mediated changes of cyclin E level as cyclin E remained stable within the treatment (Figure 4b ). In contrast, the observed diminution of cyclin A/CDK2 activity occurred simultaneously with a decreasing expression of cyclin A between 8 and 17 h (t 1/2 = 11 ± 12 h) suggesting that the inhibition of cyclin A/CDK2-associated kinase is probably due to cyclin A down-regulation. As shown in Figure 2a , the fraction of cells in G 1 phase increased markedly after 12 h of DMSO suggesting that the inhibition of cyclin A was likely a consequence of the Figure 4 Eect of DMSO on CDK2-associated kinase and on cyclin E and A expression. Cells incubated in fresh medium without (7) or with (+) DMSO for indicated times were lysed and the extracts were used in the following experiments. (a) Cyclin/CDK complexes were immunoprecipitated (IP) with anti-CDK2 (a-CDK2), anti-cyclin A (a-cycA) or anti-cyclin E (a-cycE) antibodies and the immunoprecipitates were tested for their kinase activity using histone H1 as substrate. In inset is shown the quantitation of the kinase activity obtained by counting the radioactivity incorporated in histone H1 for CDK2 (~), cyclin A (*) and cyclin E (&). 100% activity measured in untreated cells was 3.5610 5 , 2.8610 5 and 6610 4 c.p.m. incorporated in histone H1, respectively for anti-CDK2, anti-cyclin A and anti-cyclin E immunopellets. These results are from one typical experiment out of three. (b) Eect of DMSO on cyclin E, cyclin A and CDK2 expression. (Upper panel) protein extracts (100 mg) were separated on a 10% SDS ± PAGE and analysed by Western blot using speci®c anti-cyclin A or anti-cyclin E antibodies. The 55 kDa protein is the hyperphosphorylated form of cyclin E and is indicated as cyclin E*. (Lower panel) eect of DMSO on CDK2 expression and phosphorylation status. Cellular extracts (100 mg) were loaded onto 11% SDS ± PAGE and analysed by Western blotting using anti-CDK2 antibodies. The phosphorylated form of CDK2 is indicated as CDK2* cell accumulation in G 1 phase rather than a direct action of DMSO on cyclin A synthesis.
Eect of DMSO on p21
[CIP1] and p27 [KIP1] 
expression and association with CDK2 and CDK4
To determine what molecular mechanisms were involved in cyclin E/CDK2 inactivation, we examined the contribution of the cyclin-dependent kinases inhibitors (CKIs) p21
[CIP1] and p27 [KIP1] . As CDK2 is known to be a target of both p21 [CIP1] and p27 [KIP1] we have ®rst studied the eect of DMSO on the total expression of these two inhibitors. Western blot analysis of total cell extracts (Figure 5 ), demonstrated that exponentially growing 7TD1 cells contain signi®cant levels of p27 [KIP1] ( Figure  5a ). After DMSO addition, the level of p27 [KIP1] did not vary signi®cantly during the ®rst 8 h and only slightly increased (about twofold) after 12 h. This modest elevation of p27 [KIP1] did not correlate with the increase of p27
[KIP1] mRNA transcripts and thus, as reported by Hengst and Reed (1996) , probably corresponded to an increased translational rate or a decrease in the rate of degradation. Moreover, this p27
[KIP1] stimulation does not appear to be directly responsible for the inhibition of cyclin E/CDK2 complexes.
In contrast to p27 [KIP1] , in the presence of DMSO, p21
[CIP1] mRNA level increased rapidly to reach a maximal value after 4 h and decreased to the basal level between 6 and 8 h (Figure 5b, upper panel) . The induction of p21 mRNA was followed by the accumulation of p21 [CIP1] protein whose levels remained elevated for more than 8 h (Figure 5b , lower panel). This strong and early induction suggested that p21 [CIP1] might be a major mediator of CDK2 inactivation (shown in Figure 4) . Thereafter, we have examined the distribution of p21 [CIP1] and p27 [KIP1] in the dierent cyclin/CDK complexes isolated by immunoprecipitation from extracts of cells treated with or without DMSO. As shown in Figure 6a , incubation with DMSO resulted in a dramatic increase of p21 [CIP1] in both CDK2 and CDK4 complexes. This interaction increased gradually between 4 and 8 h following DMSO treatment.
Interestingly, after 8 h, we found p21 [CIP1] only in cyclin D3/CDK4 complexes (Figure 6b ) but not with cyclin D2/CDK4 complexes (not shown). However, we did not know what is the signi®cance of this association as cyclin D3/CDK4 represented a minor part of the total CDK4 activity.
In contrast to p21 [CIP1] , the pattern of p27 [KIP1] /CDK binding appeared more complex. Indeed, in nontreated cells, p27 [KIP1] was found associated with both CDK4 (70 ± 80% of the total p27 [KIP1] ) and CDK2 (20 ± 30%) (Figure 6c) . Upon DMSO addition CDK4-bound p27
[KIP1] levels markedly decreased between 6 and 8 h (about threefold) (Figure 6c ). This was con®rmed by a dramatic reduction of the p27 [KIP1] associated cyclin D2 (Figure 6c) . Interestingly, at the same time the amount of p27 [KIP1] bound to CDK2 raised 2.5-fold (Figure 6c ). As the total p27
[KIP1] level remained constant, we postulate that, following the cyclin D2 inhibition and the subsequent diminution of cyclin D2/CDK4 complexes amounts, p27
[KIP1] became available for association with cyclin/CDK2 complexes.
Our next goal was to assess the contribution of p21
[CIP1] and p27 [KIP1] in inactivating cyclin E/CDK2. To this end, cells incubated with DMSO for 8 h were lysed and CKIs-bound complexes were immunode- Figure 5 Eect of DMSO on p21
[CIP1] and p27 [KIP1] expression. (a) Analysis by Western blot of p27 [KIP1] expression in cells treated with (+) or without (7) DMSO for the indicated times. (b) Northern blot and Western blot analysis of p21 [CIP1] expression in cells treated with (+) or without (7) DMSO. Total RNA and cellular extracts were prepared as indicated in Materials and methods and p21 [CIP1] expression was analysed using a speci®c oligonucleotide probe (upper panel) or speci®c anti-p21
[CIP1] antibodies (lower panel) Figure 6 Eect of DMSO on the binding of p21 [CIP1] and p27
[KIP1] to CDK2 and CDK4 (a) Western blot analysis of p21
[CIP1] on CDK2 and CDK4 immunoprecipitates. Cells incubated with DMSO for 2, 4, 6, and 8 h were lysed and immunoprecipitated (IP) with anti-CDK2 or anti-CDK4 antibodies as described in Materials and methods and p21
[CIP1] in these complexes was detected by Western blot (WB) using a speci®c anti-p21 antibody. The right part of the ®gure correspond to the quantitative analysis of the p21 bound to CDK2 (&) and CDK4 (*). (b) Binding of p21
[CIP1] to cyclin D3/CDK4. P21 [CIP1] immunocomplexes were immunoprecipitated from the extracts derived from cells treated with (+) or without (7) DMSO for 4 and 8 h. The level of cyclin D3 in the immunoprecipitates was estimated by Western blot (WB) using a speci®c monoclonal antibody. (c) Association between p27
[KIP1] and CDK2 or CDK4. Protein extracts (2 mg) of cells untreated (7) or treated (+) with DMSO for 4, 6 or 8 h were immunoprecipitated (IP) with anti-CDK4 or anti-CDK2 and pellets were analysed by Western blot (WB) using anti-p27 [KIP1] antibodies. The quantitative analysis of CDK2-bound p27 (*) and CDK4-bound p27 (*) is shown on the right part of the ®gure. To analyse the association between p27
[KIP1] and cyclin D2, protein extracts were immunoprecipitated with anti-p27 [KIP1] antibodies (IP) and the cyclin D2 present in immunoprecipitates was detected by Western blotting using speci®c antibodies (WB). The results shown in this ®gure were from a typical experiment chosen among respectively three (a and c) and two (b) distinct experiments pleted using combination of p27 [KIP1] and p21 [CIP1] speci®c antibodies. The supernatants were then analysed by Western blotting using anti-CDK2 antibodies. We used in these experiments concentrations of anti-p27
[KIP1] and anti-p21 [CIP1] antibodies that were sucient to remove all detectable p27
[KIP1] and p21
[CIP1] present in cell extracts. The results shown in Figure 7a (left panel) indicated that 8 h after DMSO treatment 21% of total CDK2 were bound to p27 [KIP1] and to p21 [CIP1] . Further immunoprecipitation experiments carried out separately with anti-p27 [KIP1] or antip21 [CIP1] revealed that CDK2 associated with p21 [CIP1] and p27 [KIP1] to the same extent (Figure 7a , right panel). To determine the fraction of cyclin E/CDK2 associated with CKIs we analysed CDK2 in cyclin E immunoprecipitates isolated from CKI-depleted DMSO-treated extracts. The results shown in Figure  7b indicated that no detectable cyclin E/CDK2 complexes remained after p21/27 immunodepletion (right lane compared to left lane), indicating that all cyclinE/CDK2 was associated with CKIs under these conditions.
In conclusion, our experiments demonstrated that the DMSO-mediated inactivation of cyclin E/CDK2 resulted from the binding of p21 [CIP1] and p27 [KIP1] .
Discussion
The growth inhibitory properties of DMSO were usually associated with dierentiation (Kimhi et al., 1976; Kluge et al., 1976; Maeda and Sachs, 1978; Reagan et al., 1990) .
Indeed, most studies aimed at understanding the molecular mechanism(s) underlying its antimitotic action have been performed on cell lines such as HL60 and N1E-115 that dierentiate in the presence of DMSO. In these cells DMSO was found to target proteins involved in the control of the cell cycle, such as cyclins, cyclin-dependent kinases or CDK inhibitors (CKIs). In the promyelocytic HL60 cells, DMSO was shown to either reduce the expression of D1 and D2 cyclins and induces the overexpression of A, B and E cyclins (Burger et al., 1994) or to stimulate the expression of CKI p21
[CIP1] (Jiang et al., 1994) . In the mouse neuroblastoma cells N1E-115, DMSO strongly stimulated the level of the CKI p27 [KIP1] and inhibited the expression of CDK2 (Kranenburg et al., 1995) .
In this study we have found that a short incubation with DMSO of the murine hybridoma cell line 7TD1 does not lead to dierentiation or apoptosis but rather results in a reversible growth arrest in early G 1 phase as illustrated by FACS analysis and by the lack of pRb phosphorylation. We have shown that DMSO treatment inhibits cyclin D2/CDK4 and cyclin E/CDK2 kinases which is consistent with the block in G 1 phase. This inactivation could be attributed to the combined eect of the down-regulation of cyclin D2, thè redistribution' of p27 [KIP1] from CDK4 to CDK2 complexes and the induction of p21 [CIP1] . The rapid and strong down-regulation of cyclin D2 expression is probably the major cause of the inactivation of CDK4. This result is consistent with previous reports and support the notion that the inhibition of D-type cyclins may be the crucial event responsible for the antiproliferative action of numerous compounds, such as cyclic-AMP, prostaglandin A2 and alpha IFN (Gorospe et al., 1996; L'Allemain et al., 1997; Sewing et al., 1993; Tiefenbrun et al., 1996; Vadiveloo et al., 1996) . The role of cyclin D3/ CDK4 in the cell cycle of 7TD1 cells is not clear. Indeed, even though we could not detect a cyclin D3/ CDK4-associated pRb kinase activity, these complexes seem to be targets of p21 [CIP1] upon DMSO treatment, suggesting that cyclin D3 could in addition to cyclin D2/CDK4, contribute to the activation of CDK4.
In addition to the inhibition of CDK4, the DMSO treatment also leads to the inactivation of CDK2. Our data show that DMSO inhibits cyclin E-associated CDK2 activity via association with the CKIs p27 [KIP1] and p21 [CIP1] . The analysis of the dierent cyclin/ CDK2/CKIs complexes demonstrate that 50% of them are bound to p27 [KIP1] and 50% to p21 [CIP1] indicating that these two inhibitors probably act in concert to inactivate cyclin E/CDK2 complexes. In contrast to G 1 cyclins, the inactivation of cyclin A/CDK2 activity appears not to be a direct consequence of DMSO action. It results from the apparent inhibition of cyclin A likely due to the accumulation of cells arrested in G 1 phase. Thus we believe that DMSO targets speci®cally cells in G 1 phase where it promotes inactivation of G 1 cyclin/ CDK complexes.
Our experiments indicate that DMSO increases the level of p21
[CIP1] (mRNA and protein) which consequently leads to the augmentation of p21 [CIP1] /cyclin E/ CDK2 complexes. In contrast, the treatment with and p27 [KIP1] and cyclinE/CDK2 complexes. (a) Determination of the percentage of CDK2 associated with either p27 [KIP1] and/or p21
[CIP1] compared to free CDK2. Cells (5610 6 ) treated with DMSO for 8 h were solubilized and immunoprecipitated (IP) with anti-p21 (+) and/or anti-p27 (+) antibodies or incubated with non relevant serum (NRS) as described in Materials and methods. The CDK2 present in supernatants (left panel) or in the pellets (right panel) were estimated by Western blotting using speci®c antibodies. (b) Eect of DMSO on the ratio between free and p21/27-linked cyclin E/CDK2 complexes. 7TD1 cells (5610 6 ) incubated with DMSO for 8 h were solubilized and the p21/p27-associated cyclin/CDK2 complexes were immunodepleted (ID) using anti-p21
[CIP1] plus anti-p27 [KIP1] antibodies or a non relevant serum (NRS). The supernatants were then immunoprecipitated (IP) with anti-cyclin E antibodies and the level of CDK2 in the pellets was analysed by Western blotting DMSO does not result in a signi®cant accumulation of p27 [KIP1] (during the ®rst 8 h). However we show that this CKI eciently contributes to cyclin E/CDK2 inhibition. This is likely a consequence of cyclin D2 down-regulation and may be due to the redistribution of p27
[KIP1] from CDK4 to CDK2. Indeed, since in 7TD1 cells cyclin D2/CDK4 is principally associated with p27
[KIP1] the DMSO-dependent cyclin D2 inhibition provides free p27 [KIP1] molecules that can associate with cyclin E/CDK2 complexes. Similar mechanisms of CDK inhibition by p27 [KIP1] were previously reported earlier for growth inhibition mediated by TGFb and lovastatin (Chen et al., 1996; Hall et al., 1995; Peters, 1994; Poon et al., 1995) . In these situations p27
[KIP1] redistribution was attributed (i) to the inhibition of cyclin D1 expression in cells arrested by lovastatin (Poon et al., 1995) and (ii) to the synthesis of the p15 [INK4B] inhibitor in the case of TGFb (Hannon and Beach, 1994; Reynisdottir et al., 1995) . In 7TD1 cells this last possibility can be ruled out since we demonstrated that p15 [INK4B] and p16 [INK4A] are not stimulated by DMSO (data not shown).
In addition to p27
[KIP1] redistribution, we note that DMSO also induces a late accumulation of p27 [KIP1] . Even though this increase is not directly involved in the inactivation of cyclin E/CDK2 it might, in conjunction with the inhibition of cyclin D2 synthesis, provide an additional way to block CDK2 and CDK4 thus assuring an ecient block to prevent cells to initiate a new cycle.
In summary, we propose that the cell cycle arrest in G 1 phase induced by DMSO is likely the result of several molecular events that act synergistically and lead to the inhibition of cyclin D2/CDK4 and cyclin E/CDK2. Chronologically, the down-regulation of cyclin D2 appears to be the earliest event responsible for the inhibition of CDK4. The subsequent diminution of cyclin D2/CDK4 complexes leads to the redistribution of p27 [KIP1] toward cyclin E/CDK2 complexes. In parallel, the simultaneous increase of p21 [CIP1] targets cyclin D3/CDK4 but also ends to the complete inactivation of cyclin E-associated kinase and in turn inhibits synthesis of cell cycle regulators, such as cyclin A, that are required for S phase initiation and progression.
Materials and methods

Reagents
Recombinant human interleukin-6 (IL-6) puri®ed as described elsewhere (Proudfoot et al., 1993) was generously provided by Glaxo Institute for Molecular Biology (Geneva, Switzerland). Culture medium was from Life Technologies, Inc, (Cergy Pontoise, France). Dimethyl sulfoxide and fetal calf serum were from Sigma. Histone H1 was purchased from Boehringer Mannheim (Germany). Enhanced chemiluminescence (ECL) Western blotting kit reagents and the radioisotope [g-32 P]ATP were from Amersham (Les Ulis, France). Horseradish peroxidase-conjugated, rabbit anti-mouse and goat antirabbit IgG were from DAKO (Denmark). QuickHyb hybridization solution was purchased from Stratagene. PGEX-4T/2 and 5X-3 vectors, isopropyl-1-thio-b-Dgalactoside, glutathione-Sepharose 4B were from pharmacia/LKB (St-Quentin Yvelines, France).
Recombinant, GST-pRb (C-terminus pRb, amino acids 773 ± 928) (Matsushime et al., 1994) was produced in Escherichia coli, transformed by plasmid pGEX-pRb and puri®ed using a procedure described elsewhere (Rezzonico et al., 1995) .Cell culture 7TD1 mouse hybridoma cells were cultured as previously described (Rezzonico et al., 1995) in DMEM supplemented with 10% fetal calf serum and 100 U/ml of human recombinant IL-6. Thirty-six hours before the experiments, the cells were diluted into fresh medium and grown to reach a concentration of 8610 5 cells/ml. Experiments were carried out with cells resuspended at 3.5610 5 cells/ ml in fresh medium with or without 1.5% of DMSO.
Cell cycle analysis was performed by quantifying the DNA content using propidium iodide followed by analysis in¯ow cytometry using a FACScan apparatus (Beckton Dickinson) according to Vindelùv et al. (1983) .
Antibodies
The monoclonal anti-pRb antibody (G3-245) and the polyclonal anti-mouse p21
[CIP1] antiserum were obtained from Pharmingen (San Diego, CA). Antibodies to CDK4 (C-22), CDK2 (M2), cyclin E (M-20) and the anti-p27 [KIP1] antibody used in immunoprecipitation experiments (p27C-19) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The rabbit anti-cyclin A antiserum and the monoclonal anti-cyclin D3 antibody (DCS 22), were kindly provided by Dr V Dulic (Dulic et al., 1998) and Dr J Bartek (Lukas et al., 1994 (Lukas et al., , 1995 respectively. Rabbit anti-cyclin D2 antiserum was obtained by injection of recombinant Glutathione-STransferase-cyclin D2 (GST-D2). Rabbit anti-p27 [KIP1] antibodies used for Western blot experiments were raised against the N-terminal moiety (amino-acids 1 ± 90) of the mouse p27
[KIP1] coupled with GST.
Immunoprecipitations and kinase assays
For cyclin-associated H1 kinase assay, cells (10 7 ) were treated with DMSO, washed with PBS and lysed as described previously (Dulic et al., 1992) in RIPA buer, supplemented with antiproteases (1 mM phenylmethylsulfonyl¯uoride, 50 mg/ml aprotinin, 50 mg/ml leupeptin, 10 mg/ml peptatin A) and phosphatase inhibitors (20 mM NaF, 1 mM NaVO 4 ). Samples corresponding to 200 mg of total protein were immunoprecipitated with anti-CDK2, anti-cyclin E antibodies (2 ± 3 mg) (Santa-Cruz Laboratories) or anti-cyclin A antiserum (1/500) for 2 h at 48C. After incubation with protein A-Sepharose, the immunoprecipitates were recovered by centrifugation, washed ®ve times with RIPA buer, and once with RIPA buer without SDS and deoxycholate. The pellets were resuspended in 10 ml of kinase assay mixture (Tris/HCl 20 mM pH 7.8, MgCl 2 4 mM, Histone H1 2.5 mg, [g-32 P] ATP 75 mM (6500 c.p.m./pmole) and leaved to phosphorylate for 30 min at 378C (Dulic et al., 1992) . Samples were ®nally denaturated in Laemmli buer and analysed on 11% SDS ± PAGE. Gels were stained, dried and autoradiographed.
For Rb kinase assays, cyclin D/CDK4 complexes were immunoprecipitated with anti-CDK4 antibodies (3 mg) and protein A-sepharose, from 400 mg of cell extracts prepared as described by Matsushime et al. (1994) . Pellets were washed extensively in cold lysis buer and ®nally assayed for kinase activity towards soluble recombinant GST-pRb in 30 ml of HEPES 50 mM pH 7.5, MgCl 2 10 mM, EGTA 2.5 mM, DTT 1 mM, NaVO 4 1 mM, b-glycerophosphate 80 mM, ATP 20 mM, [g-32 P]ATP 5 mCi, GST-pRb 0.5 mg. After 30 min at 308C, the samples were denaturated by addition of Laemmli buer and the proteins were separated on SDS polyacrylamide gel electrophoresis (SDS ± PAGE). Finally, the gels were stained, dried and autoradiographed.
Immunoblotting
Immunoblotting of cyclin, CDK complexes, CKIs and pRb from whole cell extracts were performed with polyclonal anti-cyclin A, anti-cyclin D2, anti-cyclin E, anti-CDK2, anti-CDK4, anti-p27 [KIP1] or anti-p21 [CIP1] and monoclonal anti-pRb and anti-cyclin D3, using the following procedure. Cells were lysed in ice cold RIPA lysis buer (Tris/HCl 10 mM pH 7.8, deoxycholate 1%, NP 40 1%, SDS 0.1%, NaCl 150 mM, 10 mM NaF, 1 mM NaVO 4 , 1 mM phenylmethyl sulfonyl¯uoride (PMSF), 50 mg/ml aprotinin, 50 mg/ml leupeptin, 10 mg/ml peptatin A. Lysates were sonicated and clari®ed by centrifugation and proteins were quantitated by Bradford analysis. 100 mg protein/lane were resolved by 11% or 7.5% SDS ± PAGE and transferred on immobilon-P membrane (Millipore) in Tris 20 mM, glycin 140 mM, MetOH 20%. After saturation in PBS containing 5% milk, the antibodies or antisera were incubated at room temperature for 2 h in the same buer. Puri®ed IgG from polyclonal antibodies (anti-cyclin E, anti-p27
[KIP1] , anti-CDK2, anti-CDK4) were used at the concentration of 1 mg/ml. Anti-cyclin A, anti-p21
[CIP1] and anti-cyclin D2 antisera were respectively used at 1/500, 1/1000 and 1/250 dilutions. Monoclonal anti-pRb and anti-cyclin D3 were respectively diluted 200 and 1000 times. Secondary antibodies were used as follows: horseradish peroxidaseconjugated rabbit anti-mouse IgG (1/5000) and horseradish peroxidase-conjugated goat anti-rabbit IgG (1/ 10 000) and were incubated for 1 h at room temperature, washed three times in Tris/HCI 10 mM pH 7.8, NaCl 200 mM, Tween 20 0.05%. Signals were revealed using the Amersham ECL detection system according to the manufacturer's protocol.
Immunoprecipitation
For immunoprecipitations, cell extracts (0.25 ± 2 mg of protein), prepared as described above, were immunoprecipitated for 2 h at 48C, with anti-CDK2 (3 mg), anti-CDK4 (3 mg), anti-p27
[KIP1] (3 mg) or anti-p21 [CIP1] (1/500) and incubated with protein A-sepharose beads for 1 h. Immunocomplexes were collected by centrifugation and washed four times with cold lysis buer supplemented with anti-proteases and phosphatases inhibitors. Immunocomplexes were denaturated with Laemmli buer and submitted to SDS ± PAGE. Finally, Western blotting experiments were carried out, in conditions described above.
Northern blot analysis
Total cellular ARNs were prepared by denaturation in guanidinium thiocyanate followed by centrifugation through a cesium chloride cushion (Chirgwin et al., 1979) . Northern blot analysis was carried out using 20 mg of total RNA, following the procedure described previously (Rezzonico et al., 1995) . The cDNA probes used for the detection of p27 [KIP1] and p21 [CIP1] were generated by reverse transcription of 7TD1 total RNAs followed by polymerase chain reaction (PCR) using two sets of speci®c primers that are respectively: forward p27 [KIP1] : 5'-ATGTCAAACGTGAGAGTG; reverse p27 [KIP1] : 5'-GTAGAACTCGGGCAAG; forward p21 [CIP1] : 5'-ATGTCCAATCCTGGTGATGTC; reverse p21 [CIP1] : 5'-GTGTCAGGCTGGTCTGCCT. Probes corresponding to the full length human cyclins D1, D2 and D3 (cyl 1, 2 and 3) were generous gifts from the Dr F Cymbalista.
Quantitation Western and Northern blot analysis
The proteins and RNAs speci®cally detected by Western and Northern blot analysis were quantitated by densitometric scanning using a computerized microscopic image processor Biocom 500 (Biocom, les Ulis France) comprising a PC/AT-compatible microcomputer, a real time imagining processor, a control monitor, a color high de®nition monitor and a panasonic WV-CD50 camera.
Abbreviations CDK: cyclin-dependent kinase; CKI: cyclin-dependent kinase inhibitor; DMSO: dimethylsulfoxide; DMEM: Dulbecco's modi®ed Eagle medium; DTT: dithiothreitol; GST: glutathione S transferase; NP40: nonidet p 40; NaF: Natrium¯uoride; Na VO4: Natrium orthovanadate; PAGE: polyacrylamide gel electrophoresis; PBS: phosphate buer saline; PMSF: phenyl methyl sulfonyl uoride; pRb: retinoblastoma protein; SDS: Natrium dodecyl sulfate.
